Shukra Pharmaceuticals Ltd (SHUKRAPHAR) — shareholding pattern, promoter holding, financials and share price
About Shukra Pharmaceuticals Ltd (SHUKRAPHAR)
Shukra Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SHUKRAPHAR and on the BSE under scrip code 524632. Its ISIN is INE551C01044.
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing [1]
Shukra Pharmaceuticals Limited, founded in 1993, specializes in manufacturing and trading pharmaceutical formulations and conducting laboratory testing. Their offerings include a wide range of antibiotics, antifungal, antiviral, sedatives, and more.
The company operates four key manufacturing divisions: tablets, capsules, liquid, and small volume parental, situated in Gujarat.
Listed peers in Pharmaceuticals: Windlas Biotech Ltd, Amrutanjan Health Care Ltd, Jagsonpal Pharmaceuticals Ltd, Fredun Pharmaceuticals Ltd, Syncom Formulations (India) Ltd, Lincoln Pharmaceuticals Ltd.
Valuation & Returns
10 Jul 2026At ₹34.45 a share on 10 Jul 2026, Shukra Pharmaceuticals Ltd (SHUKRAPHAR) was valued at a price-to-earnings ratio of 57.12x against an industry P/E of 36.41x and a price-to-book of 24.01x on a book value of ₹1.44 per share as of Mar 2025. Solomo computes return on equity of 42.03% and return on capital employed of 53.84% from filed results. Earnings ratios use consolidated results for the twelve months Mar 2025 to Mar 2026.
- P/E
- 57.12x
- Industry P/E
- 36.41x
- P/B
- 24.01x
- EPS (TTM)
- ₹0.6
- Book value / share
- ₹1.44
- ROE
- 42.03%
- ROCE
- 53.84%
- ROA
- 30.44%
- Debt / equity
- 0.07x
- Dividend yield
- 0.03%
- EBITDA margin
- 58.74%
- 52-week range
- ₹17.06 – ₹65.26
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Shukra Pharmaceuticals Ltd (SHUKRAPHAR) reported revenue of ₹57 crore, net profit of ₹22 crore and earnings per share of ₹0.5. That compares with revenue of ₹33 crore and net profit of ₹10 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹6.32 crore and net profit ₹-1.72 crore (consolidated).
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue (₹ cr) | 33 | 57 |
| Net profit (₹ cr) | 10 | 22 |
| EPS (₹) | 0.22 | 0.5 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 23.57% | 18.86% | 16.73% | -56.30% |
| Profit growth | 62.81% | 206.15% | 133.65% | -48.33% |
| Stock price CAGR | 61% | 152% | 97% | 56% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 50.96% of Shukra Pharmaceuticals Ltd (SHUKRAPHAR) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0% and domestic institutional investors (DII) hold 0.11%. Market capitalisation was ₹1,508 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: RENUKA YOGESH PARIKH 19.18%, YOGESH BIHARILAL PARIKH 19.14%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 50.96% | - | 0% | 0.11% | 49.04% |
| Mar 2026 | 50.96% | - | - | 0.11% | 49.04% |
| Dec 2025 | 50.96% | - | - | 0.11% | 49.04% |
| Sep 2025 | 50.96% | - | - | 0.11% | 49.04% |
| Jun 2025 | 50.96% | - | - | 0.11% | 49.04% |
| Mar 2025 | 50.96% | - | - | 0.11% | 49.04% |
| Dec 2024 | 50.96% | - | - | 0.11% | 49.04% |
| Sep 2024 | 50.96% | - | - | 0.11% | 49.04% |